Presence and function of lytic and latent EBV antigen-specific CD8⁺ T lymphocytes in an AIDS-NHL patient (left) and an LTA individual (right).

On the x-axis, follow-up is indicated in months after HIV-1⁺ entry in the study. The arrows indicate the time of NHL-diagnosis (NHL) and start of therapy (DDI). The vertical dotted line indicates the time point at which CD4⁺ T-cell counts drop below 200/μL. (A) Longitudinal analysis of CD4⁺ and CD8⁺ T-lymphocyte numbers. (●) indicates CD4; (○), CD8. (B) Longitudinal analysis of B8-FLR–specific CD8⁺ T lymphocytes as assessed by tetramer staining (percentage of CD8⁺ T cells, solid line) and IFN-γ Elispot assay (per 10⁶ CD8⁺ T cells, dashed line). (●) indicates tetramer; (○), IFN-γ. (C) Longitudinal analysis of B8-RAK–specific CD8⁺ T lymphocytes as assessed by tetramer staining (solid line) and IFN-γ Elispot assay (dashed line). (●) indicates tetramer; (○), IFN-γ. (D) Longitudinal analysis of A2-GLC–specific CD8⁺ T lymphocytes as assessed by tetramer staining (solid line) and IFN-γ Elispot assay (dashed line), as described in “Patients, materials, and methods.” (●) indicates tetramer; (○), IFN-γ.